Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

At Protagonist, our mission is to create innovative therapies that address unmet medical needs, improve people’s lives, and bring hope to those suffering with chronic medical conditions.

We strive to become a leader in gastroenterology and hematology that enriches the lives of those we serve.

Protagonist has been the recipient of numerous awards and accolades, such as the 2020 SCRIP Award for Excellence in Drug Delivery, the 2019 Medtech Breakthrough Award for Best Pharmaceutical Delivery Technology/Platform and the 2017 APIs World Congress Award for Most Innovative Drug Delivery Technology. The Company's CEO, Dinesh V. Patel, was also named among the Top 40 Innovators of 2017 by PharmaVOICE, a publication focused on the life science industry.